Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock in a transaction dated Tuesday, October 4th. The stock was purchased at an average cost of $10.57 per share, for a total transaction of $38,052.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $32,438,812.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, September 30th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.54 per share, for a total transaction of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The shares were bought at an average cost of $10.67 per share, for a total transaction of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The shares were bought at an average cost of $11.01 per share, for a total transaction of $59,454.00.
  • On Tuesday, September 27th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $11.16 per share, for a total transaction of $20,088.00.
  • On Monday, September 26th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $11.04 per share, for a total transaction of $19,872.00.
  • On Friday, September 23rd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.95 per share, for a total transaction of $19,710.00.
  • On Thursday, September 22nd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.63 per share, for a total transaction of $19,134.00.
  • On Wednesday, September 21st, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.46 per share, for a total transaction of $18,828.00.
  • On Tuesday, September 20th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.36 per share, for a total transaction of $18,648.00.
  • On Monday, September 19th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.18 per share, for a total transaction of $18,324.00.

Shares of Opko Health Inc. (NYSE:OPK) traded up 1.89% during trading on Wednesday, reaching $10.79. 1,327,488 shares of the company were exchanged. The stock has a market capitalization of $5.94 billion and a P/E ratio of 45.15. The firm has a 50-day moving average price of $10.02 and a 200-day moving average price of $10.12. Opko Health Inc. has a 1-year low of $7.12 and a 1-year high of $11.85.

Opko Health (NYSE:OPK) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to analyst estimates of $324.11 million. The firm’s quarterly revenue was up 742.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) EPS. Equities research analysts predict that Opko Health Inc. will post ($0.05) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

OPK has been the subject of several recent analyst reports. JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Standpoint Research boosted their target price on Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, June 21st. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Opko Health in a research report on Thursday, June 16th. Jefferies Group restated a “hold” rating and set a $10.00 target price (down previously from $11.00) on shares of Opko Health in a research report on Friday, June 17th. Finally, Deutsche Bank AG dropped their target price on Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a research report on Thursday, June 16th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $13.20.

Several institutional investors have recently bought and sold shares of OPK. Janus Capital Management LLC boosted its position in Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock worth $148,000 after buying an additional 100 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock worth $214,000 after buying an additional 261 shares during the last quarter. Gilman Hill Asset Management LLC boosted its position in Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock worth $436,000 after buying an additional 298 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its position in Opko Health by 0.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 77,228 shares of the company’s stock worth $721,000 after buying an additional 612 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its position in Opko Health by 2.3% in the second quarter. Moors & Cabot Inc. now owns 61,100 shares of the company’s stock worth $571,000 after buying an additional 1,350 shares during the last quarter.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.